Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy

Journal of Pain Research

Volumn 7, Issue , 2014, Pages 339-351

  Allen, Rob ^a   Sharma, Uma ^b   Barlas, Suna ^a  

^a PFIZER INC   (United States)

^b MMS HOLDINGS INC   (United States)

Author keywords

Adaptive study design; Diabetic neuropathy; Efficacy; Neuropathic pain; Safety; Serotonin norepinephrine reuptake inhibitor

Indexed keywords

DESVENLAFAXINE; PLACEBO;

ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHY; DISEASE ASSOCIATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXPERIENCE; FATIGUE; FEMALE; HUMAN; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; LETHARGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NUMERIC RATING SCALE; OUTPATIENT; PAIN; PARALLEL DESIGN; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SOMNOLENCE; VOMITING; XEROSTOMIA;

EID: 84902245621     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S55682     Document Type: Article

References (42)

1. Tesfaye S, Vileikyte L, Rayman G, etal; on behalf of the Toronto Expert Panel on Diabetic Neuropathy. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27:629-638.
2. Jensen TS, Backonja MM, Hernandez JS, Tesfaye S, Valensi P, Ziegler D. New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res. 2006;3:108-119.
3. Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ. 2007; 335:87.
4. Lindsay TJ, Rodgers BC, Savath V, Hettinger K. Treating diabetic peripheral neuropathic pain. Am Fam Physician. 2010;82:151-158.
5. Attal N, Cruccu G, Haanpää M, etal; EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13:1153-1169.
6. Benyamin R, Trescot AM, Datta S, etal. Opioid complications and side effects. Pain Physician. 2008;11:S105-S120.
7. Lyrica [package insert]. New York, NY: Pfizer, Inc.; 2012.
8. Cymbalta [package insert]. Indianapolis, IN: Eli Lilly and Company; 2011.
9. Quilici S, Chancellor J, Löthgren M, etal. Meta-analysis of duloxetine vs pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol. 2009;9:6.
10. Kaur H, Hota D, Bhansali A, Dutta P, Bansal D, Chakrabarti A. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. Diabetes Care. 2011;34:818-822.
11. Bansal D, Bhansali A, Hota D, Chakrabarti A, Dutta P. Amitriptyline vs pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. Diabet Med. 2009;26:1019-1026.
12. Bril V, England J, Franklin GM, etal; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76:1758-1765.
13. Selvarajah D, Wilkinson ID, Davies J, Gandhi R, Tesfaye S. Central nervous system involvement in diabetic neuropathy. Curr Diab Rep. 2011;11:310-322.
14. Marks DM, Shah MJ, Patkar AA, Masand PS, Park GY, Pae CU. Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. Curr Neuropharmacol. 2009;7:331-336.
15. Deecher DC, Beyer CE, Johnston G, etal. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318:657-665.
16. Boyer P, Montgomery S, Lepola U, etal. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23:243-253.
17. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24:1877-1890.
18. Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol. 2011;31:569-576.
19. Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.; 2013.
20. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110:697-706.
21. Farrar JT, Young JP Jr, Lamoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149-158.
22. Feldman EL, Stevens MJ. Clinical testing in diabetic peripheral neuropathy. Can J Neurol Sci. 1994;21(4):S3-S7.
23. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Medical Care. 1992;30:473-483.
24. Lorr M, McNair DM, Droppleman LF. Profile of mood states technical update. Multi-Health Systems, Inc.; 2005.
25. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
26. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353-365.
27. Clayton AH, Kornstein SG, Rosas G, Guico-Pabia C, Tourian KA. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr. 2009;14:183-195.
28. Wernicke JF, Pritchett YL, D'Souza DN, etal. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411-1420.
29. Armstrong DG, Chappell AS, Le TK, etal. Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes. Pain Med. 2007;8:410-418.
30. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109-118.
31. Tolle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12: 203-213.
32. Gao Y, Ning G, Jia WP, etal. Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China. Chin Med J (Engl). 2010;123:3184-3192.
33. Moon DE, Lee DI, Lee SC, etal. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study. Clin Ther. 2010;32:2370-2385.
34. Gilron I, Wajsbrot D, Therrien F, Lemay J. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. Clin J Pain. 2011;27:185-193.
35. Boyle J, Eriksson ME, Gribble L, etal. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care. 2012;35:2451-2458.
36. Raskin J, Pritchett YL, Wang F, etal. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346-356.
37. Kadiroglu AK, Sit D, Kayabasi H, Tuzcu AK, Tasdemir N, Yilmaz ME. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complications. 2008;22:241-245.
38. Max MB, Kishore-Kumar R, Schafer SC, etal. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain. 1991;45:3-9.
39. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:1250-1256.
40. Sindrup SH, Gram LF, Skjold T, Grodum E, Brosen K, Beck-Nielsen H. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. Br J Clin Pharmacol. 1990;30:683-691.
41. Rudroju N, Bansal D, Talakokkula ST, etal. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician. 2013;16: E705-E714.
42. Kalyani RR, Saudek CD, Brancati FL, Selvin E. Association of diabetes, comorbidities, and A1c with functional disability in older adults: results from the National Health and Nutrition Examination Survey (NHANES), 1999-2006. Diabetes Care. 2010;33:1055-1060.